Risk of lymph node metastases in patients with T1b oesophageal adenocarcinoma: A retrospective single centre experience

doi:10.3748/wjg.v24.i41.4698

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 24, Issue 41

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5037)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-4) series.

Item

Count

PDF

410

HTML

2343

Figures (1-4)

150

Tables (1-4)

133

Sum=3036

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

852

Download

1149

Sum=2001

Nov 7, 2018 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastroenterol. Nov 7, 2018; 24(41): 4698-4707
Published online Nov 7, 2018. doi: 10.3748/wjg.v24.i41.4698

Table 4 Overview of patients with metastatic T1b OAC

Case	EMR tumour histopathology	Treatment after index EMR	Time till metastases (mo)¹	Additional treatment	End study outcome	Cause of death	Survival² (mo)
1	Sm2/3, G3, LVIX, R1	Surgery	4	Chemotherapy	Deceased	OAC	45
2	SmX, G3, LVI+, R1	Surgery	2	None	Alive	/	87
3	SmX, G3, LVI+, R1	Surgery	4	CRT	Deceased	OAC	8
4	Sm2/3, G3, LVI+, R1	Surgery	2	Chemotherapy	Alive	/	55
5	Sm2/3, G3, LVIX, R1	Conservative	38	CRT	Deceased	OAC	40
6	Sm2/3, G2, LVI+, R1	Conservative	4	CRT	Deceased	OAC	9
7	Sm2/3, G2, LVI-, R1	Conservative	3	CRT	Deceased	OAC	31
8	Sm2/3, G2, LVI+, R1	Conservative	4	CRT	Deceased	OAC	18
9	Sm1, G2, LVI-, R1	Conservative	17	EMR T1a, CRT	Alive	/	26
10	Sm2/3, G3, LVI-, R1	Conservative	13	Radiotherapy	Deceased	OAC	30

¹Time from index EMR until LNM/metastatic disease;

²Time from index EMR until the end of the study or death of the patient. EMR: Endoscopic mucosal resection; LNM: Lymph node metastases; Sm1: Submucosal invasion < 500 μm; Sm2/3: Submucosal invasion > 500 μm; G2: Moderately differentiated tumour; G3: Poorly differentiated tumour; LVI: Lymphovascular invasion; R0: Complete resection; R1: Incomplete resection; X: Indefinite; CRT: Chemoradiation therapy; OAC: Oesophageal adenocarcinoma; N/A: Not available.

Citation: Graham D, Sever N, Magee C, Waddingham W, Banks M, Sweis R, Al-Yousuf H, Mitchison M, Alzoubaidi D, Rodriguez-Justo M, Lovat L, Novelli M, Jansen M, Haidry R. Risk of lymph node metastases in patients with T1b oesophageal adenocarcinoma: A retrospective single centre experience. World J Gastroenterol 2018; 24(41): 4698-4707
URL: https://www.wjgnet.com/1007-9327/full/v24/i41/4698.htm
DOI: https://dx.doi.org/10.3748/wjg.v24.i41.4698